Skip to main content

Table 2 In-hospital and discharge management of the studied ACS patients with and without HF (n = 1691)

From: Characteristics and in-hospital outcomes of patients with acute coronary syndromes and heart failure in the United Arab Emirates

 

HF

Non-HF

P-value

 

(n = 356)

(n = 1335)

 

In-hospital medical treatment:

   

Aspirin

344 (96.6)

1328 (99.5)

< 0.001

Clopidogrel

336 (94.4)

1290 (96.6)

0.061

IV HEP

48 (13.5)

204 (15.3)

0.451

LMW HEP

311 (87.4)

1154 (86.4)

0.726

GP

132 (37.1)

534 (40.0)

0.329

BB

156 (43.8)

995 (74.5)

< 0.001

ACE

231 (64.9)

900 (67.4)

0.375

AIIRB

18 (5.1)

57 (4.3)

0.562

CCB

40 (11.2)

98 (7.3)

0.022

Statins

329 (92.4)

1268 (95)

0.068

Nitrates

268 (75.3)

934 (70.0)

0.056

Diuretics

242 (68.0)

158 (11.8)

< 0.001

SQ INS

160 (44.9)

368 (27.6)

< 0.001

IV INS

15 (4.2)

33 (2.5)

0.104

Discharge medical treatment:

   

Aspirin

321 (90.2)

1293 (97.0)

< 0.001

Clopidogrel

290 (81.5)

1105 (82.8)

0.812

BB

258 (72.5)

1148 (86.0)

< 0.001

ACE

252 (70.8)

999 (74.8)

0.193

AIIRB

30 (8.4)

84 (6.3)

0.151

CCB

43 (12.1)

90 (6.7)

0.001

Statins

320 (90.9)

1273 (95.4)

0.001

Nitrates

181 (51.0)

543 (40.7)

< 0.001

Diuretics

208 (58.4)

142 (10.7)

< 0.001

Antiarrythmic agents

21 (6.0)

14 (1.0)

< 0.001

Digoxin

16 (4.5)

6 (0.4)

< 0.001

Warfarin

15 (4.2)

15 (1.1)

< 0.001

In-hospital procedures:

   

Echocardiography

260 (73.0)

846 (63.4)

0.001

PCI

9 (2.5)

13 (1.0)

0.025

IABP

10 (2.8)

11 (0.8)

0.006

In-hospital outcomes:

   

Death

26 (7.3)

8 (0.6)

< 0.001

Cardiogenic shock

44 (12.4)

22 (1.7)

< 0.001

Infarction

16 (4.5)

26 (2.0)

0.011

Stroke

5 (1.4)

4 (0.3)

0.023

  1. Figures in parentheses are percentages.
  2. Abbreviations: DM diabetes mellitus, IV HEP intravenous heparin, LMW HEP low molecular weight heparin, GP glycoprotein IIb/IIIa inhibitors, BB beta-blockers, ACE angiotensin-converting enzyme inhibitors, AIIRB angiotensin II receptor blockers, CCB calcium channel blockers, SQ Insulin subcutaneous insulin, IV Insulin intravenous insulin, PCI percutaneous coronary intervention, IABP Intra-aortic balloon pump.